Search clinical trials for: Relugolix placebo

Total 53509 results

Qilu Pharmaceutical (Hainan) Co., Ltd.

Recruiting

A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain

Endometriosis

China
Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain

Endometriosis

China
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Uterine Fibroids

United States, Puerto Rico
Takeda

Completed

A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

Uterine Fibroids

Japan
Bayer

Terminated

Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb (SCHUMANN)

Endometriosis

Spain, Belgium, United States, Germany, Austria, Japan, Canada, Hungary, Bulgaria, Italy, China, Czechia, Finland, Norway, Poland, Slovakia, Estonia, Greece, Latvia, Lithuania
AbbVie

Active, not recruiting

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Uterine Fibroids | Heavy Menstrual Bleeding

United States, Puerto Rico
AbbVie (prior sponsor, Abbott)

Completed

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain (ELARIS EM-I)

Endometriosis
AbbVie

Completed

A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain (ELARIS EM-II)

Endometriosis
AbbVie

Completed

Efficacy and Safety Study of Elagolix in Women With Endometriosis

Endometriosis, Pain
AbbVie (prior sponsor, Abbott)
Neurocrine Biosciences

Completed

An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

Folliculogenesis

United States, Puerto Rico
AbbVie

Completed

Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

Polycystic Ovary Syndrome

United States, Puerto Rico
Takeda

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

Uterine Fibroids

Japan
Yale University
Pfizer

Recruiting

The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer

Prostate Cancer

United States
University of Oklahoma

Not yet recruiting

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Androgen Deprivation Therapy | Locally Advanced Prostate Cancer

United States
Yale University
University of Colorado, Denver; Eunice Kennedy Shriver National Institute of... and other collaborators

Active, not recruiting

Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis (PREGnant)

Infertility | Endometriosis

United States
Yale University
Johns Hopkins University; University of Colorado, Denver; Northwestern University and other collaborators

Recruiting

Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp (PREGnant)

Infertility | Endometriosis

United States
Yale University
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Cardiovascular Disease Risk in Women With Endometriosis

Endometriosis

United States
Sumitomo Pharma Switzerland GmbH

Active, not recruiting

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy (SERENE)

Contraception

United States, Puerto Rico
AbbVie

Completed

An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis

Endometriosis, Pain
Sumitomo Pharma Switzerland GmbH

Recruiting

Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

Pregnancy Complications | Pregnancy Related | Pregnancy, High Risk

United States
Takeda

Completed

Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids

Uterine Fibroids

Japan
University of Miami
Varian Medical Systems

Not yet recruiting

The University of Miami Adapt (UAdapt) Trial

Prostate Cancer

United States
Sumitomo Pharma Switzerland GmbH

Recruiting

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Endometriosis | Uterine Fibroids

United States
ASKA Pharmaceutical Co., Ltd.

Completed

Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis

Endometriosis

Japan
NorthShore University HealthSystem
Pfizer

Not yet recruiting

Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment

Pelvic Pain

United States
AbbVie

Completed

Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis

Endometriosis
AbbVie

Completed

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Endometriosis

United States, Canada, Puerto Rico
Myovant Sciences GmbH

Completed

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroids | Uterine Leiomyoma

United States, Italy, Poland, Czechia, Hungary, South Africa, Brazil, Chile
Myovant Sciences GmbH

Completed

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Endometriosis Related Pain

United States, Spain, Hungary, Argentina, Belgium, Bulgaria, Canada, Czechia, Finland, Poland, Portugal, South Africa, Ukraine
AbbVie

Completed

Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain

Endometriosis
AbbVie

Completed

Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain

Endometriosis
Myovant Sciences GmbH

Completed

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroid | Heavy Menstrual Bleeding

United States, Belgium, Czechia, South Africa, Chile, Brazil, Hungary, Poland
Myovant Sciences GmbH

Completed

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Endometriosis Related Pain

United States, Poland, Australia, Brazil, Chile, Czechia, Georgia, Italy, New Zealand, Romania, Sweden
Myovant Sciences GmbH

Completed

Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

Healthy

United States
Takeda

Completed

A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer

Hormone Treatment-naïve Participants With Prostate Cancer

Japan
University of Southern California

Unknown

Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist at Different Periods of the Menstrual Cycle

Ovulation; Failure or Lack of
Myovant Sciences GmbH

Completed

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroid | Heavy Menstrual Bleeding

United States, Italy, Poland, Brazil, South Africa, United Kingdom
Janssen Research & Development, LLC

Completed

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

Prostatic Neoplasms

United States
AbbVie

Completed

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

Uterine Fibroids | Heavy Menstrual Bleeding

United States, Canada
AbbVie

Completed

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Uterine Fibroids | Heavy Menstrual Bleeding

United States, Canada, Puerto Rico
Sumitomo Pharma Switzerland GmbH

Not yet recruiting

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

Pregnancy Complications | Pregnancy Related | Pregnancy, High Risk
Myovant Sciences GmbH

Completed

A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

Healthy

United States
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...

Active, not recruiting

Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms (Drugs-SNPs)

Prostate Cancer

United States
Takeda

Completed

A Food Effect Study of TAK-385 Final Formulation

Japanese Premenopausal Healthy Adult Women

Japan
Millennium Pharmaceuticals, Inc.

Completed

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

Prostate Cancer

United States, United Kingdom
Takeda

Completed

A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis

Endometriosis

Japan
AbbVie

Completed

Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis (PETAL)

Endometriosis
Montefiore Medical Center

Recruiting

Updated Diagnostic Cortisol Values for Adrenal Insufficiency

Adrenal Insufficiency

United States
Takeda

Completed

Efficacy and Safety of TAK-385 in the Treatment of Endometriosis

Endometriosis

Japan
Sumitomo Pharma Switzerland GmbH

Recruiting

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX (OPTYX)

Prostate Cancer

United States

3

Subscribe